Clinical Application of C-Reactive Protein Across the Spectrum of Acute Coronary Syndromes

(hsCRP) is associated with adverse cardiovascular out-comes in acute coronary syndromes (ACS). The ability to formulate recommendations regarding clinical use of hsCRP is limited by a paucity of data regarding several key issues. The purpose of this study was to evaluate hsCRP across the spectrum of ACS. Methods: hsCRP was measured on admission in 3225 patients with ACS. hsCRP concentrations were com-pared in patients who suffered an adverse cardiac out-come within 10 months of study entry and in patients who had no adverse event. Because of heterogeneity in the relationship between hsCRP and clinical outcomes, evaluation was limited to patients from whom samples were collected within 48 h of symptom onset. Results: Patients in the highest quartile of hsCRP com